Recursion Pharmaceuticals, Inc.(RXRX)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
RXRX | 2.12 B | - | -60.10% | 0.00% | -$0.99 | -56.58% | 7.28x | 0.00% | $7.18 | $2.77 |
VRTX | 127.55 B | 29.53x | 12.50% | 35.00% | $17.04 | 23.54% | 9.77x | 0.00% | $560.25 | $400.74 |
ALNY | 30.04 B | 41.66x | 66.90% | 16.13% | $5.39 | 96.56% | 2.21x | 0.00% | $495.55 | $197.81 |
ARWR | 8.58 B | - | 171.00% | -47.79% | -$2.25 | -55.21% | 2.96x | 0.00% | $95.49 | $34.47 |
CRSP | 4.88 B | - | 1041.40% | 0.00% | -$4.72 | -26.10% | 0.45x | 0.00% | $78.48 | $44.12 |
NTLA | 1.77 B | - | -46.20% | 0.00% | -$3.36 | -55.44% | 0.10x | 0.00% | $28.25 | $7.95 |
Peer Valuation & Performance Analysis
Peer group analysis for Recursion Pharmaceuticals, Inc. (RXRX) compared to its primary competitors (including VRTX, ALNY, ARWR) reveals distinct metrics. RXRX trades at a valuation discount relative to its competitors, with a P/E ratio of -4.0x versus the peer average of 6.0x (representing a 167% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, RXRX's revenue growth of -60.1% lags behind the peer average of 249.1%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of 0.0% is comparable to the peer average of 0.7%.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• RXRX ranks #0 in P/E ratio, #5 in revenue growth, and #3 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-08 | $4.19 | $4.20 | $3.79 | $3.95 | 30,834,100 | -7.49% |
| 2026-10-07 | $4.50 | $4.60 | $4.23 | $4.27 | 40,730,500 | -7.78% |
| 2026-10-06 | $4.81 | $5.19 | $4.39 | $4.63 | 71,106,000 | -3.14% |
| 2026-10-05 | $4.16 | $4.93 | $4.06 | $4.78 | 67,278,700 | +16.02% |
| 2026-10-02 | $4.18 | $4.27 | $4.01 | $4.12 | 18,840,000 | +1.23% |
| 2026-10-01 | $4.07 | $4.17 | $3.96 | $4.07 | 17,484,100 | -1.45% |
| 2026-09-30 | $4.09 | $4.29 | $3.98 | $4.13 | 32,785,900 | +2.48% |
| 2026-09-29 | $3.73 | $4.04 | $3.72 | $4.03 | 21,564,000 | +8.92% |
| 2026-09-28 | $3.69 | $3.84 | $3.67 | $3.70 | 13,058,800 | -1.07% |
| 2026-09-25 | $3.89 | $3.90 | $3.70 | $3.74 | 10,481,300 | -3.86% |
| 2026-09-24 | $3.65 | $3.90 | $3.61 | $3.89 | 19,338,300 | +5.14% |
| 2026-09-23 | $4.03 | $4.09 | $3.66 | $3.70 | 23,670,600 | -8.64% |
| 2026-09-22 | $4.00 | $4.16 | $3.90 | $4.05 | 40,460,400 | +2.02% |
| 2026-09-21 | $3.92 | $4.01 | $3.83 | $3.97 | 37,728,700 | +3.66% |
| 2026-09-18 | $3.54 | $3.83 | $3.50 | $3.83 | 44,325,600 | +8.19% |
Explore More Analysis for RXRX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.